Clinical Trial Update: Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1) [Phase 1]

View source ↗

Summary

Phase 1 trial AdHER2.1 investigates an adenovirus vector encoding rat HER-2 in patients with metastatic or recurrent breast cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AdHER2.1 (Adenovirus encoding rat HER-2)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Metastatic Breast Cancer, Recurrent Breast Cancer | Phase 1 | Status: COMPLETED